Role of Blood-Brain Barrier in Alzheimer’s Disease
The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
The blood-brain barrier (BBB) is involved in the pathogenesis of Alzheimer's disease (AD). BBB is a highly selective semipermeable structural and chemical barrier which ensures a stable internal environment of the brain and prevents foreign objects invading the brain tissue. BBB dysfunction induces the failure of Aβ transport from brain to the peripheral circulation across the BBB. Especially, decreased levels of LRP-1 (low density lipoprotein receptor-related protein 1) and increased levels of RAGE (receptor for advanced glycation endproducts) at the BBB can cause the failure of Aβ transport. The pathogenesis of AD is related to the BBB structural components, including pericytes, astrocytes, vascular endothelial cells, and tight junctions. BBB dysfunction will trigger neuroinflammation and oxidative stress, then enhance the activity of β-secretase and γ-secretase, and finally promote Aβ generation. A progressive accumulation of Aβ in brain and BBB dysfunction may become a feedback loop that gives rise to cognitive impairment and the onset of dementia. The correlation between BBB dysfunction and tau pathology has been well-reported. Therefore, regulating BBB function may be a new therapeutic target for treating AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661 · cited 2×
“TheBBBhasthemostimpor-tantroleinmaintainingbrainfunctionamongthe threebrainbarriers[14,15].”
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Establishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670 · cited 1×
“Pericytes, an important component of neurovascular unit and BBB, act like the gatekeepers of the BBB, and exquisitely regulate the movement of brain cellsandthetransportationofnutrientsandmoleculesbetweenthebloodandthebraininterstitialfluidthatsurroundsthebraincells [87–89].”
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier
Huber, J. D., Egleton, R. D., & Davis, T. P. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02004-x · Cited by 786 · cited 1×
“…or progression of numerous brain diseases, such as hemorrhagic and ischemic stroke, intracranial infectious diseases, intracranial autoimmune diseases, epilepsy, lupus cerebritis, and brain tumors [105, 106], as well as neurodegenerative diseases like Parkinson’s disease and AD [45, 107].”
The blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767 · cited 7×
“Second,A (cid:2) pathology suffering from BBB dysfunction can indirectly facilitate the onset of tau pathology, representing a mechanistic link between A (cid:2) /tau deposition after BBB dysfunction [1, 126].”
InfluentialAlzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672 · cited 2×
“528 Yet, the role of BBB in the pathogenesis of AD is 529 still a challenge [12, 132].”
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670
Halliday, M. R., Rege, S. V., Ma, Q., Zhao, Z., Miller, C. A., Winkler, E. A., & Zlokovic, B. V. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.44 · Cited by 649
Deane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619
The dynamic blood–brain barrier
Keaney, J., & Campbell, M. (2015) · The FEBS Journal · doi:10.1111/febs.13412 · Cited by 616 · cited 2×
“The BBB includes the main three cells: capillary endothelial cells, perivascular pericytes, and astrocyte end-feet [86].”
Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease
Cai, Z., Hussain, M. D., & Yan, L.-J. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2013.833510 · Cited by 583
RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519 · cited 1×
“Multiple studies have implicated that the LRP-1, a multifunctional cell-surface receptor, binds A (cid:2) ligand and mediates A (cid:2) endocytosis across endothelial cells at the BBB, and finally regulates A (cid:2) pathology [48, 66, 67] (Fig.”
The vascular basement membrane in the healthy and pathological brain
Thomsen, M. S., Routhe, L. J., & Moos, T. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17722436 · Cited by 490 · cited 1×
“Numerous studies suggest that astrocytes are 355 involved in the A pathology induced by its gen356 eration and clearance failure [9, 90].”
BackgroundBlood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease
Yamazaki, Y., & Kanekiyo, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091965 · Cited by 451 · cited 6×
“Abundant research results address that cerebrovascular lesions have been demonstrated to frequentlycoexistwithBBBbreakdownanddysfunc-tionintheneurodegenerativeprocessofAD[7,9, 12].”
InfluentialAge-associated Physiological and Pathological Changes at the Blood-Brain Barrier: A Review
Erdő, F., Denes, L., & de Lange, E. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16679420 · Cited by 426 · cited 2×
“Pericytes may transport A (cid:2) across the BBB into the blood [1, 9, 97].”
Deane, R., Wu, Z., & Zlokovic, B. V. (2004) · Stroke · doi:10.1161/01.str.0000143452.85382.d1 · Cited by 392
Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link
Ramos-Cejudo, J., Wisniewski, T., Marmar, C., Zetterberg, H., Blennow, K., de Leon, M. J., & Fossati, S. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.021 · Cited by 385
Clearance of amyloid-β by circulating lipoprotein receptors
Sagare, A., Deane, R., Bell, R. D., Johnson, B., Hamm, K., Pendu, R., Marky, A., Lenting, P. J., Wu, Z., Zarcone, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1635 · Cited by 373
Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery
Patching, S. G. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9672-6 · Cited by 361
Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy
Desai, B. S., Monahan, A. J., Carvey, P. M., & Hendey, B. (2007) · Cell Transplantation · doi:10.3727/000000007783464731 · Cited by 339 · cited 1×
“In addition, dysfunction of the BBB is also involved in a wide range of neurological disorders including stroke [23, 24], immune-neurological diseases [25, 26], and neurodegenerative diseases such as AD [27], Parkinson’s disease [27, 28], and multiple system atrophy [29, 30].”
Kanoski, S. E., Zhang, Y., Zheng, W., & Davidson, T. L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091414 · Cited by 324 · cited 1×
“The defi-ciency of claudin-5 and -12 in the choroid plexus and the BBB, leads to an increased BBB permeability observed in the hippocampus [115].”
Elahy, M., Jackaman, C., Mamo, J. C., Lam, V., Dhaliwal, S. S., Giles, C., Nelson, D., & Takechi, R. (2015) · Immunity & Ageing · doi:10.1186/s12979-015-0029-9 · Cited by 300 · cited 1×
“The key TJs proteins are identified as relevant for AD, including Zona occludens-1 (ZO-1), occludin, claudin-1, claudin-3, claudin-5, claudin-11, claudin-12, claudin-19, and tricellulin [112, 113].”
Kanekiyo, T., & Bu, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00093 · Cited by 281
Jaeger, L. B., Dohgu, S., Sultana, R., Lynch, J. L., Owen, J. B., Erickson, M. A., Shah, G. N., Price, T. O., Fleegal-Demotta, M. A., Butterfiled, D. A., et al. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.01.017 · Cited by 281 · cited 1×
“BBB dysfunction enhances A (cid:2) generation. dysfunction in the neuroinflammation pathogenesis of AD has been also well reported, which in turn the neuroinflammation is closely linked to A (cid:2) generation [36, 37].”
Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
Wu, Z., Guo, H., Chow, N., Sallstrom, J., Bell, R. D., Deane, R., Brooks, A. I., Kanagala, S., Rubio, A., Sagare, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1287 · Cited by 280
Oxidative stress and β-amyloid protein in Alzheimer’s disease
Cai, Z., Zhao, B., & Ratka, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8155-9 · Cited by 279
Self-citationThe Pericyte: A Forgotten Cell Type with Important Implications for Alzheimer's Disease?
Winkler, E. A., Sagare, A. P., & Zlokovic, B. V. (2014) · Brain Pathology · doi:10.1111/bpa.12152 · Cited by 278
Xiang, Y., Bu, X.-L., Liu, Y.-H., Zhu, C., Shen, L.-L., Jiao, S.-S., Zhu, X.-Y., Giunta, B., Tan, J., Song, W.-H., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1477-1 · Cited by 277 · cited 1×
“Substantive evidence now implicates that 173 this A pathology is involved in not only its exces174 sive production and then its abnormal deposition and 175 accumulation, but failure of A clearance from brain 176 to the peripheral circulation as well [10, 41].”
BackgroundNishitsuji, K., Hosono, T., Nakamura, T., Bu, G., & Michikawa, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.225532 · Cited by 275
Barrier function in the peripheral and central nervous system—a review
Reinhold, A., & Rittner, H. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-016-1920-8 · Cited by 275 · cited 1×
“The key TJs proteins are identified as relevant for AD, including Zona occludens-1 (ZO-1), occludin, claudin-1, claudin-3, claudin-5, claudin-11, claudin-12, claudin-19, and tricellulin [112, 113].”
A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
Atwal, J. K., Chen, Y., Chiu, C., Mortensen, D. L., Meilandt, W. J., Liu, Y., Heise, C. E., Hoyte, K., Luk, W., Lu, Y., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002254 · Cited by 274
Kook, S.-Y., Hong, H. S., Moon, M., Ha, C. M., Chang, S., & Mook-Jung, I. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.6102-11.2012 · Cited by 265
Najjar, S., Pearlman, D. M., Devinsky, O., Najjar, A., & Zagzag, D. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-142 · Cited by 248 · cited 1×
“The permeability of the BBB 121 increases under the following factors, such as brain 122 edema, brain tumor, ionizing radiation injury, inflam123 mation, and other pathological conditions [20].”
Hartz, A. M. S., Bauer, B., Soldner, E. L. B., Wolf, A., Boy, S., Backhaus, R., Mihaljevic, I., Bogdahn, U., Klünemann, H. H., Schuierer, G., et al. (2012) · Stroke · doi:10.1161/strokeaha.111.627562 · Cited by 248
Janelidze, S., Hertze, J., Nägga, K., Nilsson, K., Nilsson, C., Wennström, M., van Westen, D., Blennow, K., Zetterberg, H., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.11.017 · Cited by 237 · cited 1×
“Multiple research results 530 address that there is no relationship between A 531 pathology and BBB permeability [35, 133].”
BackgroundFormation and maintenance of the BBB
Blanchette, M., & Daneman, R. (2015) · Mechanisms of Development · doi:10.1016/j.mod.2015.07.007 · Cited by 236 · cited 1×
“…or progression of numerous brain diseases, such as hemorrhagic and ischemic stroke, intracranial infectious diseases, intracranial autoimmune diseases, epilepsy, lupus cerebritis, and brain tumors [105, 106], as well as neurodegenerative diseases like Parkinson’s disease and AD [45, 107].”
Najjar, S., Pahlajani, S., De Sanctis, V., Stern, J. N. H., Najjar, A., & Chong, D. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00083 · Cited by 221
Emanuele, E., D’Angelo, A., Tomaino, C., Binetti, G., Ghidoni, R., Politi, P., Bernardi, L., Maletta, R., Bruni, A. C., & Geroldi, D. (2005) · Archives of Neurology · doi:10.1001/archneur.62.11.1734 · Cited by 218 · cited 1×
“Reduced levels 294 of sRAGE in the plasma of patients with AD have 295 also been reported, compared with that for those with 296 either vascular dementia or with normal controls [80].”
ResultGiri, R., Shen, Y., Stins, M., Du Yan, S., Schmidt, A. M., Stern, D., Kim, K.-S., Zlokovic, B., & Kalra, V. K. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.279.6.c1772 · Cited by 218
Miners, J. S., Schulz, I., & Love, S. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17690761 · Cited by 208
Song, H., Li, Y., Lee, J., Schwartz, A. L., & Bu, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3379 · Cited by 186 · cited 1×
“It is also a key signaling protein which is involved in various biological processes, such as lipoprotein metabolism and cell motility, and diseases, such as AD [59], ischemic stroke [60, 61], cerebral amyloid angiopathy [59, 62], atherosclerosis [58, 63], and cancer [64, 65].”
Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice
Krohn, M., Lange, C., Hofrichter, J., Scheffler, K., Stenzel, J., Steffen, J., Schumacher, T., Brüning, T., Plath, A.-S., Alfen, F., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57867 · Cited by 183
Amyloid β Oligomers Disrupt Blood–CSF Barrier Integrity by Activating Matrix Metalloproteinases
Brkic, M., Balusu, S., Van Wonterghem, E., Gorlé, N., Benilova, I., Kremer, A., Van Hove, I., Moons, L., De Strooper, B., Kanazir, S., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0006-15.2015 · Cited by 182
Evolution of blood-brain-barrier permeability after acute ischemic stroke
Merali, Z., Huang, K., Mikulis, D., Silver, F., & Kassner, A. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171558 · Cited by 167 · cited 1×
“In addition, dysfunction of the BBB is also involved in a wide range of neurological disorders including stroke [23, 24], immune-neurological diseases [25, 26], and neurodegenerative diseases such as AD [27], Parkinson’s disease [27, 28], and multiple system atrophy [29, 30].”
Blood-Brain Barrier: Interface Between Internal Medicine and the Brain
PARDRIDGE, W. M., OLDENDORF, W. H., CANCILLA, P., & FRANK, H. J. L. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-82 · Cited by 160 · cited 1×
“Accumulat384 ing studies have illustrated the ease with which BBB 385 dysfunction and damaged TJs structural integrity 386 result in occurrence or progression of numerous 387 brain diseases, such as hemorrhagic and ischemic 388 stroke, intracranial infectious diseases, intracranial 389 autoimmune diseases, epilepsy, l…”
McCarthy, R. C., & Kosman, D. J. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1771-4 · Cited by 156 · cited 1×
“Astrocytic dysfunction easily damages the nor360 mal physiological functions of BBB, and induces 361 the imbalance of A clearance at the BBB from the 362 brain parenchyma into blood [97, 99].”
Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier
Spencer, J. I., Bell, J. S., & DeLuca, G. C. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316011 · Cited by 151
Disruption of Bmal1 Impairs Blood–Brain Barrier Integrity via Pericyte Dysfunction
Nakazato, R., Kawabe, K., Yamada, D., Ikeno, S., Mieda, M., Shimba, S., Hinoi, E., Yoneda, Y., & Takarada, T. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3639-16.2017 · Cited by 138
Astrocyte and Alzheimer’s disease
Cai, Z., Wan, C., & Liu, Z. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8593-x · Cited by 135 · cited 1×
“Meanwhile, astrocytes act a critical role in the transport of A (cid:2) across the BBB which is regulated by RAGE and LRP-1 in endothelial cells [67, 100].”
Self-citationCandela, P., Gosselet, F., Saint-Pol, J., Sevin, E., Boucau, M.-C., Boulanger, E., Cecchelli, R., & Fenart, L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100462 · Cited by 128
The Role of Pericytes in Neurovascular Unit Remodeling in Brain Disorders
ElAli, A., Thériault, P., & Rivest, S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046453 · Cited by 122
Phan, D. T., Bender, R. H. F., Andrejecsk, J. W., Sobrino, A., Hachey, S. J., George, S. C., & Hughes, C. C. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217694100 · Cited by 120
The blood brain barrier in Alzheimer’s disease
Chakraborty, A., de Wit, N. M., van der Flier, W. M., & de Vries, H. E. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2016.11.008 · Cited by 118 · cited 2×
“Abundant research results address that cerebrovascular lesions have been demonstrated to frequentlycoexistwithBBBbreakdownanddysfunc-tionintheneurodegenerativeprocessofAD[7,9, 12].”
Blood–brain barrier and blood–cerebrospinal fluid barrier in normal and pathological conditions
Ueno, M., Chiba, Y., Murakami, R., Matsumoto, K., Kawauchi, M., & Fujihara, R. (2016) · Brain Tumor Pathology · doi:10.1007/s10014-016-0255-7 · Cited by 116
Lalla, E., Lamster, I. B., & Schmidt, A. M. (1998) · Annals of Periodontology · doi:10.1902/annals.1998.3.1.13 · Cited by 115 · cited 1×
“advanced glycation end products (AGEs), high251 mobility group box protein 1 (HMGB1), S100 252 proteins, lipopolysaccharide, -sheet fibrils, and A 253 [70, 71].”
Park, J., Baik, S. H., Han, S., Cho, H. J., Choi, H., Kim, H. J., Choi, H., Lee, W., Kim, D. K., & Mook‐Jung, I. (2017) · Aging Cell · doi:10.1111/acel.12530 · Cited by 115
The Blood–Brain Barrier in Alzheimer's Disease
Sharma, H. S., Castellani, R. J., Smith, M. A., & Sharma, A. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00003-x · Cited by 111
Choi, B.-R., Cho, W.-H., Kim, J., Lee, H. J., Chung, C., Jeon, W. K., & Han, J.-S. (2014) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.147 · Cited by 111 · cited 2×
“Fur261 thermore, A accumulation in brain resulting from 262 RAGE-mediated A transporting across the BBB 263 will trigger or amplify a common proinflammatory 264 response [72, 73].”
BackgroundResultABCG2- and ABCG4-Mediated Efflux of Amyloid-β Peptide 1-40 at the Mouse Blood-Brain Barrier
Do, T. M., Noel-Hudson, M.-S., Ribes, S., Besengez, C., Smirnova, M., Cisternino, S., Buyse, M., Calon, F., Chimini, G., Chacun, H., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-112189 · Cited by 109
Nikolakopoulou, A. M., Zhao, Z., Montagne, A., & Zlokovic, B. V. (2017) · PLOS ONE · doi:10.1371/journal.pone.0176225 · Cited by 109
Modelling the Neurovascular Unit and the Blood-Brain Barrier with the Unique Function of Pericytes
Vandenhaute, E., Dehouck, L., Boucau, M.-C., Sevin, E., Uzbekov, R., Tardivel, M., Gosselet, F., Fenart, L., Cecchelli, R., & Dehouck, M.-P. (2011) · Current Neurovascular Research · doi:10.2174/156720211798121016 · Cited by 106
Matrix Metalloproteinase in Blood-Brain Barrier Breakdown in Dementia
Weekman, E. M., & Wilcock, D. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150759 · Cited by 106 · cited 1×
“The over419 activated matrix metalloproteinases (MMPs) degrade 420 both the extracellular matrix and these TJs between 421 endothelial cells [117].”
Mackic, J. B., Weiss, M. H., Miao, W., Kirkman, E., Ghiso, J., Calero, M., Bading, J., Frangione, B., & Zlokovic, B. V. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70010210.x · Cited by 101
Transporters in the Brain Endothelial Barrier
Ueno, M., Nakagawa, T., Wu, B., Onodera, M., Huang, C.-L., Kusaka, T., Araki, N., & Sakamoto, H. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790827816 · Cited by 100
Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease
Wang, C. Y., Finstad, C. L., Walfield, A. M., Sia, C., Sokoll, K. K., Chang, T.-Y., Fang, X. D., Hung, C. H., Hutter-Paier, B., & Windisch, M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.031 · Cited by 98
Disruption of the blood-brain barrier in parkinson's disease: curse or route to a cure?
Lee, H. (2014) · Frontiers in Bioscience · doi:10.2741/4206 · Cited by 96 · cited 1×
“In addition, dysfunction of the BBB is also 133 involved in a wide range of neurological disorders 134 including stroke [23, 24], immune-neurological dis135 eases [25, 26], and neurodegenerative diseases such 136 as AD [27], Parkinson’s disease [27, 28], and multiple 137 system atrophy [29, 30].”
Giri, R., Selvaraj, S., Miller, C. A., Hofman, F., Yan, S. D., Stern, D., Zlokovic, B. V., & Kalra, V. K. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00293.2001 · Cited by 93
Askarova, S., Yang, X., Sheng, W., Sun, G. Y., & Lee, J. C.-M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.038 · Cited by 92
Spampinato, S. F., Merlo, S., Sano, Y., Kanda, T., & Sortino, M. A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14068 · Cited by 90
Candela, P., Saint‐Pol, J., Kuntz, M., Boucau, M., Lamartinière, Y., Gosselet, F., & Fénart, L. (2014) · Brain Research · doi:10.1016/j.brainres.2014.10.047 · Cited by 87 · cited 1×
“Pericytes, an important component of neurovascular unit and BBB, act like the gatekeepers of the BBB, and exquisitely regulate the movement of brain cellsandthetransportationofnutrientsandmoleculesbetweenthebloodandthebraininterstitialfluidthatsurroundsthebraincells [87–89].”
The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease.
Schmidt, A. M., Sahagan, B. G., Nelson, R. B., Selmer, J., Rothlein, R., & Bell, J. M. (2009) · PubMed · Cited by 86
Hofrichter, J., Krohn, M., Schumacher, T., Lange, C., Feistel, B., Walbroel, B., Heinze, H.-J., Crockett, S., F.Sharbel, T., & Pahnke, J. (2013) · Current Alzheimer Research · doi:10.2174/15672050113106660171 · Cited by 86
Go, G.-W. (2015) · Nutrients · doi:10.3390/nu7064453 · Cited by 85 · cited 1×
“…as alpha-2-macroglobulin receptor (A2MR), apolipoprotein E receptor (APOER) or cluster of differentiation 91 (CD91), is a member of the low-density lipoprotein receptor family, which facilitates its multiple functions as a ligand receptor for endocytosis in the plasma membrane of cells [57, 58].”
Machida, T., Dohgu, S., Takata, F., Matsumoto, J., Kimura, I., Koga, M., Nakamoto, K., Yamauchi, A., & Kataoka, Y. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.03.026 · Cited by 84
Wang, H., Chen, F., Du, Y., Long, Y., Reed, M. N., Hu, M. Y., Suppiramaniam, V. D., Hong, H., & Tang, S. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.026 · Cited by 84
Yancey, P. G., Ding, Y., Fan, D., Blakemore, J. L., Zhang, Y., Ding, L., Zhang, J., Linton, M. F., & Fazio, S. (2011) · Circulation · doi:10.1161/circulationaha.111.032268 · Cited by 83
Wan, W., Chen, H., & Li, Y. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2013.825258 · Cited by 81
Shang, D. S., Yang, Y. M., Zhang, H., Tian, L., Jiang, J. S., Dong, Y. B., Zhang, K., Li, B., Zhao, W. D., Fang, W. G., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16660983 · Cited by 69
Blood–Brain Barrier Integrity in Alzheimer's Disease Patients and Elderly Control Subjects
Caserta, M. T., Caccioppo, D., Lapin, G. D., Ragin, A., & Groothuis, D. R. (1998) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.10.1.78 · Cited by 67 · cited 1×
“Neuropathologi43 cal blood vessels, which are commonly in the elderly 44 people, are more significantly correlated to the classi45 cal pathological hallmarks of AD (NFTs and amyloid 46 plaques) [5, 6].”
Tau Proteins Cross the Blood-Brain Barrier
Banks, W. A., Kovac, A., Majerova, P., Bullock, K. M., Shi, M., & Zhang, J. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160542 · Cited by 67 · cited 1×
“Finally, several tau proteins (Tau-441, Tau-410, truncated Tau 151–391, and truncated Tau 121–227) can cross the BBB bi-directonally, and blood-borne tau proteins may enhance brain tau pathology [129].”
Goldwaser, E. L., Acharya, N. K., Sarkar, A., Godsey, G., & Nagele, R. G. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160284 · Cited by 65
Hong-xin, F., Zhang, Y., Liu, T., Zhang, X., & Wu, S. (2017) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2017.1399788 · Cited by 65
The Role of Interleukin-18, Oxidative Stress and Metabolic Syndrome in Alzheimer’s Disease
Ojala, J., & Sutinen, E. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6050055 · Cited by 64 · cited 1×
“Third, both neuroinflamma-tion and oxidative stress induced by BBB damage can accelerate the development of tau hyperphosphorylation and NFT formation [127, 128].”
Davis, J., Xu, F., Miao, J., Previti, M. L., Romanov, G. A., Ziegler, K., & Nostrand, W. E. V. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.05.031 · Cited by 63
Occludin is overexpressed in Alzheimer's disease and vascular dementia
Romanitan, M. O., Popescu, B. O., Winblad, B., Bajenaru, O. A., & Bogdanovic, N. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00047.x · Cited by 61 · cited 1×
“The overexpression of occludin was found in both AD and vascular dementia [114].”
Altered expression of claudin family proteins in Alzheimer's disease and vascular dementia brains
Romanitan, M. O., Popescu, B. O., Spulber, Å., BaÌjenaru, O., Popescu, L. M., Winblad, B., & Bogdanovic, N. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00999.x · Cited by 61 · cited 1×
“Strong evidence has been provided so far that damaged TJs structural integrity will try to wield inappropriate influence in the AD pathogenesis [9, 108–110].”
Ashok, A., Rai, N. K., Raza, W., Pandey, R., & Bandyopadhyay, S. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.013 · Cited by 61
Song, J., Choi, S.-M., Whitcomb, D. J., & Kim, B. C. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.491 · Cited by 61
Erratum: Clearance systems in the brain—implications for Alzheimer diseaser
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.36 · Cited by 61
Do, T. M., Dodacki, A., Alata, W., Calon, F., Nicolic, S., Scherrmann, J.-M., Farinotti, R., & Bourasset, F. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150350 · Cited by 60
Tight junctions in neurological diseases
Bednarczyk, J., & Lukasiuk, K. (2011) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2011-1861 · Cited by 60
Liang, F., Jia, J., Wang, S., Qin, W., & Liu, G. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2012.06.005 · Cited by 59 · cited 3×
“Meanwhile, astrocytes act a critical role in the transport of A (cid:2) across the BBB which is regulated by RAGE and LRP-1 in endothelial cells [67, 100].”
Masuda, H., Mori, M., Uchida, T., Uzawa, A., Ohtani, R., & Kuwabara, S. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.01.024 · Cited by 57 · cited 1×
“In addition, dysfunction of the BBB is also 133 involved in a wide range of neurological disorders 134 including stroke [23, 24], immune-neurological dis135 eases [25, 26], and neurodegenerative diseases such 136 as AD [27], Parkinson’s disease [27, 28], and multiple 137 system atrophy [29, 30].”
Kuntz, M., Candela, P., Saint-Pol, J., Lamartinière, Y., Boucau, M.-C., Sevin, E., Fenart, L., & Gosselet, F. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150469 · Cited by 55
Lue, L.-F., Walker, D. G., Jacobson, S., & Sabbagh, M. (2009) · Future Neurology · doi:10.2217/14796708.4.2.167 · Cited by 54 · cited 2×
“Generally, A (cid:2) -ligand binding to full-length RAGE helps stimulate sustained AD pathological injury resulting in inflammation and oxidative stress, and is ultimately conducive to increased RAGE expression [77].”
Zhang, G., Tian, Y., Huang, J., Tao, R., Liao, M., Lu, Y., Ye, W., Wang, R., Fukunaga, K., Lou, Y., et al. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12032 · Cited by 54
McCarty, J. H. (2005) · Assay and Drug Development Technologies · doi:10.1089/adt.2005.3.89 · Cited by 54
Imaging of Leukocyte Trafficking in Alzheimer’s Disease
Pietronigro, E., Zenaro, E., & Constantin, G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00033 · Cited by 53
Ahn, H. J., Chen, Z.-L., Zamolodchikov, D., Norris, E. H., & Strickland, S. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000368 · Cited by 53
Acute formaldehyde exposure induced early Alzheimer-like changes in mouse brain
Liu, X., Zhang, Y., Wu, R., Ye, M., Zhao, Y., Kang, J. M., Ma, P., Li, J., & Yang, X. (2017) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2017.1368053 · Cited by 50 · cited 1×
“It is possible that either astro371 cytic dysfunction or activated astrocyte promotes the 372 permeability of the BBB underlying the pathway 373 of oxidative stress and inflammation, induces early 374 AD-like pathology in the C57BL/6 mice brain, and 375 facilitates the susceptibility of AD [101, 103].”
de Gonzalo‐Calvo, D., Cenarro, A., Martínez-Bujidos, M., Badimón, L., Bayés‐Genís, A., Ordóñez‐Llanos, J., Civeira, F., & Llorente‐Cortés, V. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.085 · Cited by 49
Pan, Y., Khalil, H., & Nicolazzo, J. (2015) · Current Clinical Pharmacology · doi:10.2174/157488471003150820151532 · Cited by 49 · cited 1×
“Yet, the role of BBB in the pathogenesis of AD is still a challenge [12, 132].”
The β-amyloid peptide compromises Reelin signaling in Alzheimer’s disease
Cuchillo-Ibañez, I., Mata-Balaguer, T., Balmaceda, V., Arranz, J. J., Nimpf, J., & Sáez-Valero, J. (2016) · Scientific Reports · doi:10.1038/srep31646 · Cited by 47
Patel, P., & Shah, J. (2017) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2017.06.007 · Cited by 46
Cerebral Amyloid Angiopathy, Blood-Brain Barrier Disruption and Amyloid Accumulation in SAMP8 Mice
del Valle, J., Duran-Vilaregut, J., Manich, G., Pallàs, M., Camins, A., Vilaplana, J., & Pelegrí, C. (2011) · Neurodegenerative Diseases · doi:10.1159/000324757 · Cited by 45
Beneš, P., Jurajda, M., Žaloudík, J., Hollá, L. I., & Vácha, J. (2003) · Breast Cancer Research · doi:10.1186/bcr591 · Cited by 44 · cited 1×
“It is also a key signaling 218 protein which is involved in various biological 219 processes, such as lipoprotein metabolism and cell 220 motility, and diseases, such as AD [59], ischemic 221 stroke [60, 61], cerebral amyloid angiopathy [59, 222 62], atherosclerosis [58, 63], and cancer [64, 65].”
Krueger, M., Härtig, W., Frydrychowicz, C., Mueller, W. C., Reichenbach, A., Bechmann, I., & Michalski, D. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16670922 · Cited by 44 · cited 1×
“In addition, dysfunction of the BBB is also involved in a wide range of neurological disorders including stroke [23, 24], immune-neurological diseases [25, 26], and neurodegenerative diseases such as AD [27], Parkinson’s disease [27, 28], and multiple system atrophy [29, 30].”
Zhang, L., Postina, R., & Wang, Y. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0121-4 · Cited by 43
LRP-Mediated Clearance of Aβ is Inhibited by KPI-Containing Isoforms of APP
Moir, R., & Tanzi, R. (2005) · Current Alzheimer Research · doi:10.2174/1567205053585918 · Cited by 42 · cited 1×
“bioactivities of these two receptors at the BBB may 199 be a feasible method of controlling A pathology 200 and lowering its secondary damage, such as neuroin201 flammation, oxidative injury, dysfunction of synaptic 202 transmission, neuronal loss, increased A influx at 203 the BBB, as well as parenchymal and neurovas…”
Song, S. K., Lee, S.-K., Lee, J. J., Lee, J. E., Choi, H. S., Sohn, Y. H., & Lee, P. H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.12.017 · Cited by 41
Zhang, W., Xiong, H., Callaghan, D., Liu, H., Jones, A., Pei, K., Fatehi, D., Brunette, E., & Stanimirovic, D. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-13 · Cited by 41
Sagare, A. P., Bell, R. D., Srivastava, A., Sengillo, J. D., Singh, I., Nishida, Y., Chow, N., & Zlokovic, B. V. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.439570 · Cited by 40
Spellerberg, B., Prasad, S., Cabellos, C., Burroughs, M., Cahill, P. A., & TUOMANEN, E. I. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.4.1037 · Cited by 40 · cited 1×
“In this condition, 130 an effective concentration of penicillin in brain tissue 131 can be achieved and be beneficial to disease treatment 132 [21, 22].”
Wang, M. Y., Ross-Cisneros, F. N., Aggarwal, D., Liang, C.-Y., & Sadun, A. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0513-4 · Cited by 38
The Designed Environment and How it Affects Brain Morphology and Mental Health
Golembiewski, J. A. (2015) · HERD Health Environments Research & Design Journal · doi:10.1177/1937586715609562 · Cited by 38 · cited 1×
“Emerging models and techniques have demon78 strated the importance of brain health microenvi79 ronment in keeping all aspects of brain function 80 and from pathological injury [13].”
MethodTauopathies – Focus on Changes at the Neurovascular Unit
Michalicová, A., Banks, W. A., Legáth, J., & Kováč, A. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170203143336 · Cited by 37
Brain Capillaries in Alzheimer’s Disease
Balogiannis, S. (2015) · Journal of Neurology & Stroke · doi:10.15406/jnsk.2015.02.00069 · Cited by 36
Plasma levels of soluble receptor for advanced glycation end products in Alzheimer's disease
Xu, X.-Y., Deng, C.-Q., Wang, J., Deng, X.-J., Xiao, Q., Li, Y., He, Q., Fan, W.-H., Quan, F.-Y., Zhu, Y.-P., et al. (2017) · International Journal of Neuroscience · doi:10.1080/00207454.2016.1193861 · Cited by 35 · cited 1×
“More notable, though, is that sRAGE, the extracellular ligand-binding decoy of RAGE, may blockade the ligand-RAGE interaction, and then suppress A (cid:2) -RAGE interaction and prevent extracellular A (cid:2) into cells or circulating A (cid:2) into brain parenchyma [67, 78, 79].”
Ruzali, W. A. W., Kehoe, P. G., & Love, S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121336 · Cited by 34
Griffin, J. M., Kho, D., Graham, E. S., Nicholson, L. F. B., & O’Carroll, S. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157483 · Cited by 32
Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis
Leung, S. S., Forbes, J. M., & Borg, D. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0782-y · Cited by 32 · cited 1×
“There are a series of RAGE ligands, including advanced glycation end products (AGEs), high-mobility group box protein 1 (HMGB1), S100 proteins, lipopolysaccharide, (cid:2) -sheet fibrils, and A (cid:2) [70, 71].”
Yin, K., Jin, J., Zhu, X., Yu, L., Wang, S., Qian, L., Han, L., & Xu, Y. (2017) · Neurological Research · doi:10.1080/01616412.2017.1348689 · Cited by 32 · cited 1×
“Various studies have evidenced 205 that regulating the levels of RAGE and LRP-1 mod206 ulates A metabolism including its transport and 207 clearance [55, 56].”
Tan, S., Shan, Y., Wang, Y., Lin, Y., Liao, S., Deng, Z., Zhou, L., Cai, W., Zeng, Q., Zhang, L., et al. (2017) · Clinical Science · doi:10.1042/cs20170984 · Cited by 31 · cited 1×
“acid are more easily passed through the BBB, while 115 many ions (generally smaller molecular weight) are 116 difficult to pass, even cannot pass through the BBB 117 [18, 19].”
Humanin Exerts Neuroprotection During Cardiac Ischemia-Reperfusion Injury
Kumfu, S., Charununtakorn, S. T., Jaiwongkam, T., Chattipakorn, N., & Chattipakorn, S. C. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170708 · Cited by 31 · cited 1×
“Third, both neuroinflamma-tion and oxidative stress induced by BBB damage can accelerate the development of tau hyperphosphorylation and NFT formation [127, 128].”
Current status of 18F-DOPA PET imaging in the detection of brain tumor recurrence.
Calabria, F. F., & Cascini, G. L. (2015) · PubMed · doi:10.1967/s0024499100211 · Cited by 26
The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview
Jakki, S. L., Venkatachalam, S., Ramesh, Y. V., Chandrasekar, M., & Vijayaraghavan, C. (2017) · Current Drug Targets · doi:10.2174/1389450118666170612100750 · Cited by 20 · cited 1×
“Over494 all, BBB dysfunction could initiate tau pathology, 495 which is causally involved in the development of AD 496 [130, 131].”
BackgroundOhtsuki, S., Ito, S., & Terasaki, T. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.160 · Cited by 19
Lok, K. Z., Manzanero, S., & Arumugam, T. V. (2016) · Brain Research · doi:10.1016/j.brainres.2016.05.023 · Cited by 16 · cited 1×
“It is also a key signaling protein which is involved in various biological processes, such as lipoprotein metabolism and cell motility, and diseases, such as AD [59], ischemic stroke [60, 61], cerebral amyloid angiopathy [59, 62], atherosclerosis [58, 63], and cancer [64, 65].”
Lee, J. E., Song, S., Hong, J. Y., Sunwoo, M.-K., Park, H.-J., Sohn, Y. H., & Lee, P. H. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.12.002 · Cited by 11 · cited 1×
“In addition, dysfunction of the BBB is also 133 involved in a wide range of neurological disorders 134 including stroke [23, 24], immune-neurological dis135 eases [25, 26], and neurodegenerative diseases such 136 as AD [27], Parkinson’s disease [27, 28], and multiple 137 system atrophy [29, 30].”
BackgroundNiego, B., Broughton, B. R. S., Ho, H., Sobey, C. G., & Medcalf, R. L. (2017) · Fluids and Barriers of the CNS · doi:10.1186/s12987-017-0081-2 · Cited by 8
Janowitz, H. D., & Schneierson, S. S. (1948) · PubMed · Cited by 6
Research works printed but not linked: 1
- Volpina, 2015, [Fragment of receptor for advanced glycation end products improves memory state in a model of Alzheimer’s disease, Bioorg Khim, 41, 709
Cited by
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
“The presence of BBB avoids the brain from damage by keeping a stable environment.(28,29) But it also limits the drugs that enter into the CNS for treating brain diseases such as neurodegenerative diseases and brain cancer.”
BackgroundHan, L., & Jiang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.023 · Cited by 358
Więckowska-Gacek, A., Mietelska-Porowska, A., Wydrych, M., & Wojda, U. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101397 · Cited by 343
“…the molecular mechanisms responsible for BBB function and much attention has been paid to BBB deterioration in neurological diseases including AD, as extensively reviewed (Cai et al., 2018; Costea et al., 2019; Profaci et al., 2020; Sweeney et al., 2018, 2019b; Yamazaki and Kanekiyo, 2017).”
Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Stanciu, G. D., Luca, A., Rusu, R. N., Bild, V., Beschea Chiriac, S. I., Solcan, C., Bild, W., & Ababei, D. C. (2019) · Biomolecules · doi:10.3390/biom10010040 · Cited by 297
Magnetic iron oxide nanoparticles for brain imaging and drug delivery
Qiao, R., Fu, C., Forgham, H., Javed, I., Huang, X., Zhu, J., Whittaker, A. K., & Davis, T. P. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114822 · Cited by 245
Metadata
- Authors
- Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q.
- Affiliations
- Department of Neurology, Chongqing General Hospital, Chongqing, Chongqing, China
- Corresponding author
- Cai, Zhiyou
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-05-30
- Volume
- 63
- Issue
- 4
- Pages
- 1223-1234
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2804234159
- Cited by
- 370
- References
- 133
- Citations by year
- 2026: 31 · 2025: 59 · 2024: 63 · 2023: 69 · 2022: 49 · 2021: 63 · 2020: 25 · 2019: 10 · 2018: 1
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- blood-brain barrier, Alzheimer's disease
- MeSH terms
- Receptor for Advanced Glycation End Products, Alzheimer Disease, Blood-Brain Barrier, Humans, Amyloid beta-Peptides, Low Density Lipoprotein Receptor-Related Protein-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.